Cartesian Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
Cartesian Therapeutics, Inc. (RNAC) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-03-13
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$740.00K.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- Cartesian Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$740.00K 10-K · filed 2025-03-13 | ||
| 2023-09-30 | -$740.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 10-K · filed 2024-03-07 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $0.00 derived: sum of 2 quarters · filed 2024-03-07 | $0.00 10-K · filed 2024-03-07 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$461.00K derived: sum of 2 quarters · filed 2023-03-02 | -$461.00K 10-K · filed 2023-03-02 | |
| 2020-09-30 | -$461.00K 10-Q · filed 2021-11-09 | -$461.00K 10-Q · filed 2021-11-09 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $0.00 derived: sum of 2 quarters · filed 2021-03-12 | $0.00 10-K · filed 2021-03-12 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$673.00K derived: sum of 2 quarters · filed 2020-03-12 | -$673.00K 10-K · filed 2020-03-12 | |
| 2017-09-30 | -$673.00K 10-Q · filed 2018-11-08 | -$673.00K 10-Q · filed 2018-11-08 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $0.00 derived: sum of 2 quarters · filed 2019-03-15 | $0.00 10-K · filed 2019-03-15 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |